search
Back to results

Investigation of the Effects of Curcumin and Resveratrol Supplements Added to the Mediterranean Diet on Disease Severity and Inflammatory Biomarkers in Patients With Ulcerative Colitis

Primary Purpose

Ulcerative Colitis

Status
Recruiting
Phase
Not Applicable
Locations
Turkey
Study Type
Interventional
Intervention
Mediterranean Diet
Curcumin Supplementation
Resveratrol Supplementation
Sponsored by
Ardahan University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Ulcerative Colitis focused on measuring Ulcerative Colitis, Mediterranean diet, Curcumin, Resveratrol, inflammatory bowel disease

Eligibility Criteria

18 Years - 70 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Male and female patients aged >18 years, Those previously diagnosed with ulcerative colitis and/or newly diagnosed with clinical course, consistent histology and endoscopy by a gastroenterologist, Mild and Moderate activity disease was confirmed by the Truelove-Witts Severity Index, Using a fixed dose of 5 - aminosalicylic acid (mesalazine) and/or azathioprine, Who did not receive nutrition therapy in the last 3 months, Not using anti-inflammatory drugs and antibiotic drugs in the last 4 weeks, Not using curcumin and resveratrol supplements before participating in the study, Agreeing to participate in the study voluntarily, Exclusion Criteria: Women during pregnancy or lactation Not meeting the inclusion criteria, History of chronic disease (such as diabetes), hypothyroidism and hyperthyroidism, liver, kidney and cardiovascular diseases, polycystic ovary syndrome and Cushing's syndrome, Taking one of the anti-inflammatory and antibiotic drugs,

Sites / Locations

  • Inonu University Turgut Ozal Medical CenterRecruiting
  • Malatya Training and Research HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Active Comparator

Experimental

Experimental

Arm Label

Mediterranean Diet

Curcumin Supplementation

Resveratrol Supplementation

Arm Description

The individuals in this group will be given a nutrition model in accordance with the Mediterranean Nutrition Program under the supervision of a dietitian for 8 weeks. Individuals will be informed about the Mediterranean diet, their questions will be answered, the current food consumption record will be examined by the dietitian and they will be asked to follow the nutrition program prepared in the most appropriate way (by considering energy, nutrient requirements and nutritional habits). Every 15 days, the nutrition program will be updated with the meetings to be made by the dietitian and the patient, and the applicability of the program will be checked through daily communication.

In addition to the Mediterranean Diet program in the 1st group for individuals in this group; 800 mg of curcumin supplement (VeNatura Curcumin Supplementary Food, Vefa, Istanbul, Turkey) will be given as 1 capsule each in the morning and evening meals.

In addition to the Mediterranean Diet in the 1st group for individuals in this group; 250 mg resveratrol supplement (VeNatura Resveratrol Supplementary Food, Vefa, Istanbul, Turkey) will be given as 1 capsule each in the morning and evening meals.

Outcomes

Primary Outcome Measures

Inflammatory Bowel Disease Questionnaire (IBDQ)
The questionnaire consists of 32 questions and 4 subsections. These sections are; systemic symptoms (5 questions), emotional function (12 questions), social function (5 questions) and intestinal symptoms (10 questions). The questionnaire consists of a 7-point Likert scale system. For each question, 1 point indicates the highest level of exposure, and 7 indicates that there is no problem. Scores range from 32 to 224, with a higher score associated with higher quality of life. Turkish version of IBDQ will be used to assess patients' quality of life.
Mediterranean Diet Assessment Tool (14-MEDAS)
The Mediterranean Diet Assessment Tool will be used to measure the adherence of the participants to the Mediterranean diet. In the 14-question scale, 1 or 0 points are taken for each question asked according to the amount of consumption and these points are added. Scores are evaluated as ≀5 (low ), 6-9 (moderate), and β‰₯10 (high agreement).

Secondary Outcome Measures

36-Item Short Form Survey (SF-36)
It is the most frequently used quality of life scale in the medical field and consists of 8 sub-parameters with a total of 36 items that evaluate physical and mental health. These sub-parameters are physical function, physical role limitation, pain, general health, vitality, social function, emotional role limitation, and mental health. The scores range from 0-100, with 100 points indicating the best health condition and 0 points the worst health condition.
Truelove-Witts Severity Index
Truelove-Witts Severity Index is a clinical classification categorizes the disease as mild, moderate, and severe, based on a combination of clinical and laboratory parameters, including bowel movements, rectal bleeding, fever, tachycardia, anemia, and increased sedimentation. The Truelove-Witts classification, using clinical symptoms, is applicable to patients with ulcerative colitis,and it is easy and reliable to use in the clinic.
Body Mass Index
Body weight measurements and height of the volunteers will be taken with height meter and scale. All measurements will be taken in light clothing and without shoes, according to International Standards for Anthropometric Assessment (ISAK) guidelines. Body mass index (BMI) will be calculated with weight (kg) / height (m)^2 formula. Results will be interpreted as kg/m^2.
Waist Hip Circumference Ratio
Non-stretchable tape measure will be used for waist and hip circumference. All measurements will be taken in light clothing and without shoes, according to International Standards for Anthropometric Assessment (ISAK) guidelines. Waist hip circumference ratio will be calculated with waist circumference (cm) / hip circumference (cm).
Daily energy intake
Food frequency will be evaluated by The Turkish Ministry of Health version of Food Frequency Questionnaire (FFQ). FFQ is a limited check list of foods and beverages with a frequency response section for subjects to report how often each item was consumed over the last three months. Food Record (FR) will be evaluated dietary recall. The patient will be asked to note down the foods she consumes for last 3 days. The obtained data from FFQ and FR will be entered into the BeBiS 7.1 software (BeBiS Comp., Istanbul, Turkey) and the daily energy intake(kcal) will be calculated.
Daily protein, fat, carbohydrate and fiber intake
Food frequency will be evaluated by The Turkish Ministry of Health version of Food Frequency Questionnaire (FFQ). FFQ is a limited check list of foods and beverages with a frequency response section for subjects to report how often each item was consumed over the last three months. Food Record (FR) will be evaluated dietary recall. The patient will be asked to note down the foods she consumes for last 3 days. The obtained data from FFQ and FR will be entered into the BeBiS 7.1 software (BeBiS Comp., Istanbul, Turkey) and the daily protein, fat, carbohydrate, fiber (gram) intake will be calculated.
Daily vitamin and mineral intake (mg)
Food frequency will be evaluated by The Turkish Ministry of Health version of Food Frequency Questionnaire (FFQ). FFQ is a limited check list of foods and beverages with a frequency response section for subjects to report how often each item was consumed over the last three months. Food Record (FR) will be evaluated dietary recall. The patient will be asked to note down the foods she consumes for last 3 days. The obtained data from FFQ and FR will be entered into the BeBiS 7.1 software (BeBiS Comp., Istanbul, Turkey) and the daily vitamin (E, B1, B2, niacin, C) and mineral (sodium, potassium, magnesium, phosphorus, iron, zinc) (mg) intake will be calculated.
Daily vitamin and mineral intake (mcg)
Food frequency will be evaluated by The Turkish Ministry of Health version of Food Frequency Questionnaire (FFQ). FFQ is a limited check list of foods and beverages with a frequency response section for subjects to report how often each item was consumed over the last three months. Food Record (FR) will be evaluated dietary recall. The patient will be asked to note down the foods she consumes for last 3 days. The obtained data from FFQ and FR will be entered into the BeBiS 7.1 software (BeBiS Comp., Istanbul, Turkey) and the daily vitamin (A, D, K, Folate, B12) and mineral (iodine) (mcg) intake will be calculated.
24 Hour Recall Physical Activity Record
Individuals who will participate in the research will be asked to record the physical activities they have done within 24 hours, in minutes, and to bring them to the week in which nutritional counseling will begin. Thus, after anthropometric measurements are made on the individuals, the resting metabolic rate (RMH) will be calculated with the Harris Benedict equation and the total energy requirements will be determined together with the physical activity coefficient found by using the 24-hour physical activity record.
C-Reactive Protein
The blood tests were performed during routine controls. The C-Reactive Protein (mg/dL) biomarkers parameters to be examined.
Hemoglobin
The blood tests were performed during routine controls. The Hemoglobin (g/dL) to be examined.
Mean Corpuscular Hemoglobin
The blood tests were performed during routine controls. The Mean Corpuscular Hemoglobin (pg) parameter to be examined.
Mean Platelet Volume and Platelet Distribution Width (fL)
The blood tests were performed during routine controls. The blood biomarkers parameters to be examined are as follows: Mean Platelet Volume (fL) Platelet Distribution Width (fL) All blood biomarkers will be interpret separately.
Erythrocyte Sedimentation Rate (mm/hour)
The blood tests were performed during routine controls. The blood biomarkers parameters to be examined are as follows: Erythrocyte Sedimentation Rate (mm/hour)
White blood cell and Thrombocyte (10^3/uL)
The blood tests were performed during routine controls. The blood biomarkers parameters to be examined are as follows: White blood cell (10^3/uL) Thrombocyte (10^3/uL) All blood biomarkers will be interpret separately.
Blood biomarkers (%)
The blood tests were performed during routine controls. The blood biomarkers parameters to be examined are as follows: Hematocrit (%) Pro-calcitonin (%) Lymphocyte (%) Monocyte (%) Neutrophil (%) Eosinophil (%) Basophil (%) Immune Globulin G (%) Platelet-Large cell ratio (%) Red Cell Distribution Width (%)

Full Information

First Posted
February 11, 2023
Last Updated
March 7, 2023
Sponsor
Ardahan University
search

1. Study Identification

Unique Protocol Identification Number
NCT05761327
Brief Title
Investigation of the Effects of Curcumin and Resveratrol Supplements Added to the Mediterranean Diet on Disease Severity and Inflammatory Biomarkers in Patients With Ulcerative Colitis
Official Title
Investigation of the Effects of Curcumin and Resveratrol Supplements Added to the Mediterranean Diet on Disease Severity and Inflammatory Biomarkers in Patients With Ulcerative Colitis
Study Type
Interventional

2. Study Status

Record Verification Date
March 2023
Overall Recruitment Status
Recruiting
Study Start Date
June 3, 2022 (Actual)
Primary Completion Date
February 1, 2023 (Actual)
Study Completion Date
March 28, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Ardahan University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The aim of the study was to examine and compare the effects of Mediterranean diet, curcumin supplementation with Mediterranean diet in individuals with ulcerative colitis, and resveratrol supplementation with Mediterranean diet in individuals with ulcerative colitis, on disease symptoms, quality of life, and inflammatory biomarkers.
Detailed Description
In the light of the information in the literature, it is seen that the level of evidence in the existing literature is insufficient with the data obtained in terms of dietary approaches and nutritional supplements to be applied to individuals with Ulcerative Colitis (UC). In addition, when the literature was examined, no randomized controlled study was found that specifically examined the effects of the Mediterranean diet and nutritional supplements combined with diet in individuals with UC, and also compared the effects of two different nutritional supplements applied in combination with diet. In this direction, the aims of this research are; Mediterranean diet in individuals with UC, Curcumin supplement taken together with the Mediterranean diet in individuals with UC, Resveratrol supplement taken with the Mediterranean diet in individuals with UC, To examine and compare their effects on disease symptoms, quality of life and inflammatory biomarkers. Hypotheses of the Research; H0a: Mediterranean diet has no effect on disease symptoms, quality of life an inflammatory biomarkers in individuals with UC. H0b: Curcumin supplementation in addition to the Mediterranean diet has no effect on disease symptoms, quality of life, and inflammatory biomarkers in individuals with UC. H0c: Resveratrol supplementation in addition to the Mediterranean diet has no effect on disease symptoms, quality of life and inflammatory biomarkers in individuals with UC. H0d: Three approaches including Mediterranean diet, curcumin and resveratrol supplements applied in addition to diet in individuals with UC; compared to each other in terms of disease symptoms, quality of life, and inflammatory biomarkers.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Ulcerative Colitis
Keywords
Ulcerative Colitis, Mediterranean diet, Curcumin, Resveratrol, inflammatory bowel disease

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Intervention Group 1: Mediterranean Diet Intervention Group 2: Mediterranean Diet + Curcumin Supplementation Intervention Group 3: Mediterranean Diet + Resveratrol Supplementation
Masking
None (Open Label)
Allocation
Randomized
Enrollment
45 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Mediterranean Diet
Arm Type
Active Comparator
Arm Description
The individuals in this group will be given a nutrition model in accordance with the Mediterranean Nutrition Program under the supervision of a dietitian for 8 weeks. Individuals will be informed about the Mediterranean diet, their questions will be answered, the current food consumption record will be examined by the dietitian and they will be asked to follow the nutrition program prepared in the most appropriate way (by considering energy, nutrient requirements and nutritional habits). Every 15 days, the nutrition program will be updated with the meetings to be made by the dietitian and the patient, and the applicability of the program will be checked through daily communication.
Arm Title
Curcumin Supplementation
Arm Type
Experimental
Arm Description
In addition to the Mediterranean Diet program in the 1st group for individuals in this group; 800 mg of curcumin supplement (VeNatura Curcumin Supplementary Food, Vefa, Istanbul, Turkey) will be given as 1 capsule each in the morning and evening meals.
Arm Title
Resveratrol Supplementation
Arm Type
Experimental
Arm Description
In addition to the Mediterranean Diet in the 1st group for individuals in this group; 250 mg resveratrol supplement (VeNatura Resveratrol Supplementary Food, Vefa, Istanbul, Turkey) will be given as 1 capsule each in the morning and evening meals.
Intervention Type
Other
Intervention Name(s)
Mediterranean Diet
Intervention Description
In the Mediterranean diet; The frequency of consumption of foods such as olive oil, olives, nuts, fish, vegetables and fruits will be given in accordance with the Mediterranean diet pyramid. During the study, it is planned to develop new recipes suitable for the nutritional habits of the individual. The researcher will be able to reach the researcher 7/24 in case of any problem experienced by the individual, and the participant's questions will be answered. Nutrition counseling to this group will be supported by an oral explanation given by the dietitian.
Intervention Type
Dietary Supplement
Intervention Name(s)
Curcumin Supplementation
Intervention Description
Participants will take a daily supplement of 1600 mg of curcumin. It is planned that the participants will use 120 capsules of curcumin supplement during the research.
Intervention Type
Dietary Supplement
Intervention Name(s)
Resveratrol Supplementation
Intervention Description
Participants will take a 500mg resveratrol supplement daily. Participants are planned to use 120 capsules of resveratrol supplement during the study.
Primary Outcome Measure Information:
Title
Inflammatory Bowel Disease Questionnaire (IBDQ)
Description
The questionnaire consists of 32 questions and 4 subsections. These sections are; systemic symptoms (5 questions), emotional function (12 questions), social function (5 questions) and intestinal symptoms (10 questions). The questionnaire consists of a 7-point Likert scale system. For each question, 1 point indicates the highest level of exposure, and 7 indicates that there is no problem. Scores range from 32 to 224, with a higher score associated with higher quality of life. Turkish version of IBDQ will be used to assess patients' quality of life.
Time Frame
Change from baseline Inflammatory Bowel Disease Questionnaire total score at 8 weeks
Title
Mediterranean Diet Assessment Tool (14-MEDAS)
Description
The Mediterranean Diet Assessment Tool will be used to measure the adherence of the participants to the Mediterranean diet. In the 14-question scale, 1 or 0 points are taken for each question asked according to the amount of consumption and these points are added. Scores are evaluated as ≀5 (low ), 6-9 (moderate), and β‰₯10 (high agreement).
Time Frame
Change from baseline Mediterranean Diet Assessment Tool total score at 8 weeks
Secondary Outcome Measure Information:
Title
36-Item Short Form Survey (SF-36)
Description
It is the most frequently used quality of life scale in the medical field and consists of 8 sub-parameters with a total of 36 items that evaluate physical and mental health. These sub-parameters are physical function, physical role limitation, pain, general health, vitality, social function, emotional role limitation, and mental health. The scores range from 0-100, with 100 points indicating the best health condition and 0 points the worst health condition.
Time Frame
Change from baseline physical function, physical role limitation, pain, general health, vitality, social function, emotional role limitation, and mental health scores at 8 weeks
Title
Truelove-Witts Severity Index
Description
Truelove-Witts Severity Index is a clinical classification categorizes the disease as mild, moderate, and severe, based on a combination of clinical and laboratory parameters, including bowel movements, rectal bleeding, fever, tachycardia, anemia, and increased sedimentation. The Truelove-Witts classification, using clinical symptoms, is applicable to patients with ulcerative colitis,and it is easy and reliable to use in the clinic.
Time Frame
Change from baseline Truelove-Witts Severity Index score at 8 weeks
Title
Body Mass Index
Description
Body weight measurements and height of the volunteers will be taken with height meter and scale. All measurements will be taken in light clothing and without shoes, according to International Standards for Anthropometric Assessment (ISAK) guidelines. Body mass index (BMI) will be calculated with weight (kg) / height (m)^2 formula. Results will be interpreted as kg/m^2.
Time Frame
Change from baseline BMI at 8 weeks
Title
Waist Hip Circumference Ratio
Description
Non-stretchable tape measure will be used for waist and hip circumference. All measurements will be taken in light clothing and without shoes, according to International Standards for Anthropometric Assessment (ISAK) guidelines. Waist hip circumference ratio will be calculated with waist circumference (cm) / hip circumference (cm).
Time Frame
Change from baseline Waist hip circumference ratio at 8 weeks
Title
Daily energy intake
Description
Food frequency will be evaluated by The Turkish Ministry of Health version of Food Frequency Questionnaire (FFQ). FFQ is a limited check list of foods and beverages with a frequency response section for subjects to report how often each item was consumed over the last three months. Food Record (FR) will be evaluated dietary recall. The patient will be asked to note down the foods she consumes for last 3 days. The obtained data from FFQ and FR will be entered into the BeBiS 7.1 software (BeBiS Comp., Istanbul, Turkey) and the daily energy intake(kcal) will be calculated.
Time Frame
Change from baseline from the daily energy intake at 8 weeks
Title
Daily protein, fat, carbohydrate and fiber intake
Description
Food frequency will be evaluated by The Turkish Ministry of Health version of Food Frequency Questionnaire (FFQ). FFQ is a limited check list of foods and beverages with a frequency response section for subjects to report how often each item was consumed over the last three months. Food Record (FR) will be evaluated dietary recall. The patient will be asked to note down the foods she consumes for last 3 days. The obtained data from FFQ and FR will be entered into the BeBiS 7.1 software (BeBiS Comp., Istanbul, Turkey) and the daily protein, fat, carbohydrate, fiber (gram) intake will be calculated.
Time Frame
Change from baseline from the daily protein, fat, carbohydrate and fiber intake at 8 weeks
Title
Daily vitamin and mineral intake (mg)
Description
Food frequency will be evaluated by The Turkish Ministry of Health version of Food Frequency Questionnaire (FFQ). FFQ is a limited check list of foods and beverages with a frequency response section for subjects to report how often each item was consumed over the last three months. Food Record (FR) will be evaluated dietary recall. The patient will be asked to note down the foods she consumes for last 3 days. The obtained data from FFQ and FR will be entered into the BeBiS 7.1 software (BeBiS Comp., Istanbul, Turkey) and the daily vitamin (E, B1, B2, niacin, C) and mineral (sodium, potassium, magnesium, phosphorus, iron, zinc) (mg) intake will be calculated.
Time Frame
Change from baseline from the daily vitamin and mineral intake (mg) at 8 weeks
Title
Daily vitamin and mineral intake (mcg)
Description
Food frequency will be evaluated by The Turkish Ministry of Health version of Food Frequency Questionnaire (FFQ). FFQ is a limited check list of foods and beverages with a frequency response section for subjects to report how often each item was consumed over the last three months. Food Record (FR) will be evaluated dietary recall. The patient will be asked to note down the foods she consumes for last 3 days. The obtained data from FFQ and FR will be entered into the BeBiS 7.1 software (BeBiS Comp., Istanbul, Turkey) and the daily vitamin (A, D, K, Folate, B12) and mineral (iodine) (mcg) intake will be calculated.
Time Frame
Change from baseline from the daily vitamin and mineral intake (mcg) at 8 weeks
Title
24 Hour Recall Physical Activity Record
Description
Individuals who will participate in the research will be asked to record the physical activities they have done within 24 hours, in minutes, and to bring them to the week in which nutritional counseling will begin. Thus, after anthropometric measurements are made on the individuals, the resting metabolic rate (RMH) will be calculated with the Harris Benedict equation and the total energy requirements will be determined together with the physical activity coefficient found by using the 24-hour physical activity record.
Time Frame
Pre-intervention: Beginning of the study
Title
C-Reactive Protein
Description
The blood tests were performed during routine controls. The C-Reactive Protein (mg/dL) biomarkers parameters to be examined.
Time Frame
Change from baseline C-Reactive Protein (mg/dL) at 8 weeks.
Title
Hemoglobin
Description
The blood tests were performed during routine controls. The Hemoglobin (g/dL) to be examined.
Time Frame
Change from baseline hemoglobin (g/dL) at 8 weeks.
Title
Mean Corpuscular Hemoglobin
Description
The blood tests were performed during routine controls. The Mean Corpuscular Hemoglobin (pg) parameter to be examined.
Time Frame
Change from baseline Mean Corpuscular Hemoglobin (pg) at 8 weeks.
Title
Mean Platelet Volume and Platelet Distribution Width (fL)
Description
The blood tests were performed during routine controls. The blood biomarkers parameters to be examined are as follows: Mean Platelet Volume (fL) Platelet Distribution Width (fL) All blood biomarkers will be interpret separately.
Time Frame
Change from baseline Mean Platelet Volume and Platelet Distribution Width (fL) at 8 weeks.
Title
Erythrocyte Sedimentation Rate (mm/hour)
Description
The blood tests were performed during routine controls. The blood biomarkers parameters to be examined are as follows: Erythrocyte Sedimentation Rate (mm/hour)
Time Frame
Change from baseline Erythrocyte Sedimentation Rate (mm/hour) at 8 weeks.
Title
White blood cell and Thrombocyte (10^3/uL)
Description
The blood tests were performed during routine controls. The blood biomarkers parameters to be examined are as follows: White blood cell (10^3/uL) Thrombocyte (10^3/uL) All blood biomarkers will be interpret separately.
Time Frame
Change from baseline White blood cell and Thrombocyte (10^3/uL) at 8 weeks.
Title
Blood biomarkers (%)
Description
The blood tests were performed during routine controls. The blood biomarkers parameters to be examined are as follows: Hematocrit (%) Pro-calcitonin (%) Lymphocyte (%) Monocyte (%) Neutrophil (%) Eosinophil (%) Basophil (%) Immune Globulin G (%) Platelet-Large cell ratio (%) Red Cell Distribution Width (%)
Time Frame
Change from baseline blood parameters (%) at 8 weeks.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Male and female patients aged >18 years, Those previously diagnosed with ulcerative colitis and/or newly diagnosed with clinical course, consistent histology and endoscopy by a gastroenterologist, Mild and Moderate activity disease was confirmed by the Truelove-Witts Severity Index, Using a fixed dose of 5 - aminosalicylic acid (mesalazine) and/or azathioprine, Who did not receive nutrition therapy in the last 3 months, Not using anti-inflammatory drugs and antibiotic drugs in the last 4 weeks, Not using curcumin and resveratrol supplements before participating in the study, Agreeing to participate in the study voluntarily, Exclusion Criteria: Women during pregnancy or lactation Not meeting the inclusion criteria, History of chronic disease (such as diabetes), hypothyroidism and hyperthyroidism, liver, kidney and cardiovascular diseases, polycystic ovary syndrome and Cushing's syndrome, Taking one of the anti-inflammatory and antibiotic drugs,
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Γ–zge EROL DOĞAN, MSc
Phone
+905535053683
Email
ozgeerol@ardahan.edu.tr
Facility Information:
Facility Name
Inonu University Turgut Ozal Medical Center
City
Malatya
ZIP/Postal Code
44200
Country
Turkey
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yasir Furkan Γ‡AĞIN, MD, Assoc. Prof
Phone
+904223410660
Email
yasir.cagin@inonu.edu.tr
First Name & Middle Initial & Last Name & Degree
Γ–zge EROL DOĞAN, MSc
First Name & Middle Initial & Last Name & Degree
Yasir Furkan Γ‡AĞIN, Assoc. Prof.
First Name & Middle Initial & Last Name & Degree
Kezban Esen KARACA Γ‡ELΔ°K, Assoc. Prof.
First Name & Middle Initial & Last Name & Degree
Murat BAŞ, Professor
Facility Name
Malatya Training and Research Hospital
City
Malatya
ZIP/Postal Code
44200
Country
Turkey
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
EyΓΌp Hakan ALAN, MD
Phone
+905066002677
Email
drhakanalan@gmail.com
First Name & Middle Initial & Last Name & Degree
EyΓΌp Hakan ALAN, MD

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
Citation
Judge TA LG. Inflammatory Bowel Disease. In: Friedman SL MK, Grendell JH, editor. CURRENT Diagnosis&Treatment in Gastroenterology 2th ed. America: McGraw-Hill Companies; 2003.
Results Reference
background
PubMed Identifier
15168364
Citation
Sands BE. From symptom to diagnosis: clinical distinctions among various forms of intestinal inflammation. Gastroenterology. 2004 May;126(6):1518-32. doi: 10.1053/j.gastro.2004.02.072. No abstract available.
Results Reference
background
PubMed Identifier
26316768
Citation
Kothari M, Mudireddy P, Swaminath A. Patient considerations in the management of ulcerative colitis - role of vedolizumab. Ther Clin Risk Manag. 2015 Aug 19;11:1235-42. doi: 10.2147/TCRM.S65650. eCollection 2015.
Results Reference
background
PubMed Identifier
22001864
Citation
Molodecky NA, Soon IS, Rabi DM, Ghali WA, Ferris M, Chernoff G, Benchimol EI, Panaccione R, Ghosh S, Barkema HW, Kaplan GG. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012 Jan;142(1):46-54.e42; quiz e30. doi: 10.1053/j.gastro.2011.10.001. Epub 2011 Oct 14.
Results Reference
background
PubMed Identifier
27741097
Citation
Bernstein CN, Eliakim A, Fedail S, Fried M, Gearry R, Goh KL, Hamid S, Khan AG, Khalif I, Ng SC, Ouyang Q, Rey JF, Sood A, Steinwurz F, Watermeyer G, LeMair A; Review Team:. World Gastroenterology Organisation Global Guidelines Inflammatory Bowel Disease: Update August 2015. J Clin Gastroenterol. 2016 Nov/Dec;50(10):803-818. doi: 10.1097/MCG.0000000000000660. No abstract available.
Results Reference
background
PubMed Identifier
18724251
Citation
Tozun N, Atug O, Imeryuz N, Hamzaoglu HO, Tiftikci A, Parlak E, Dagli U, Ulker A, Hulagu S, Akpinar H, Tuncer C, Suleymanlar I, Ovunc O, Hilmioglu F, Aslan S, Turkdogan K, Bahcecioglu HI, Yurdaydin C; Members of the Turkish IBD Study Group. Clinical characteristics of inflammatory bowel disease in Turkey: a multicenter epidemiologic survey. J Clin Gastroenterol. 2009 Jan;43(1):51-7. doi: 10.1097/MCG.0b013e3181574636.
Results Reference
background
PubMed Identifier
21530745
Citation
Cosnes J, Gower-Rousseau C, Seksik P, Cortot A. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology. 2011 May;140(6):1785-94. doi: 10.1053/j.gastro.2011.01.055.
Results Reference
background
PubMed Identifier
12472908
Citation
Ardizzone S, Bianchi Porro G. Inflammatory bowel disease: new insights into pathogenesis and treatment. J Intern Med. 2002 Dec;252(6):475-96. doi: 10.1046/j.1365-2796.2002.01067.x.
Results Reference
background
PubMed Identifier
25724700
Citation
Lang A, Salomon N, Wu JC, Kopylov U, Lahat A, Har-Noy O, Ching JY, Cheong PK, Avidan B, Gamus D, Kaimakliotis I, Eliakim R, Ng SC, Ben-Horin S. Curcumin in Combination With Mesalamine Induces Remission in Patients With Mild-to-Moderate Ulcerative Colitis in a Randomized Controlled Trial. Clin Gastroenterol Hepatol. 2015 Aug;13(8):1444-9.e1. doi: 10.1016/j.cgh.2015.02.019. Epub 2015 Feb 24.
Results Reference
background
PubMed Identifier
17101300
Citation
Hanai H, Iida T, Takeuchi K, Watanabe F, Maruyama Y, Andoh A, Tsujikawa T, Fujiyama Y, Mitsuyama K, Sata M, Yamada M, Iwaoka Y, Kanke K, Hiraishi H, Hirayama K, Arai H, Yoshii S, Uchijima M, Nagata T, Koide Y. Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol. 2006 Dec;4(12):1502-6. doi: 10.1016/j.cgh.2006.08.008. Epub 2006 Nov 13.
Results Reference
background
PubMed Identifier
32888128
Citation
Sabzevary-Ghahfarokhi M, Soltani A, Luzza F, Larussa T, Rahimian G, Shirzad H, Bagheri N. The protective effects of resveratrol on ulcerative colitis via changing the profile of Nrf2 and IL-1beta protein. Mol Biol Rep. 2020 Sep;47(9):6941-6947. doi: 10.1007/s11033-020-05753-4. Epub 2020 Sep 4.
Results Reference
background
PubMed Identifier
29191255
Citation
Nunes S, Danesi F, Del Rio D, Silva P. Resveratrol and inflammatory bowel disease: the evidence so far. Nutr Res Rev. 2018 Jun;31(1):85-97. doi: 10.1017/S095442241700021X. Epub 2017 Dec 1.
Results Reference
background
PubMed Identifier
31802559
Citation
Sadeghi N, Mansoori A, Shayesteh A, Hashemi SJ. The effect of curcumin supplementation on clinical outcomes and inflammatory markers in patients with ulcerative colitis. Phytother Res. 2020 May;34(5):1123-1133. doi: 10.1002/ptr.6581. Epub 2019 Dec 4.
Results Reference
background

Learn more about this trial

Investigation of the Effects of Curcumin and Resveratrol Supplements Added to the Mediterranean Diet on Disease Severity and Inflammatory Biomarkers in Patients With Ulcerative Colitis

We'll reach out to this number within 24 hrs